
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. has positioned itself advantageously within the ophthalmic pharmaceutical market, benefiting from the increasing penetration of biosimilars, which have captured over 40% market share in relevant therapeutic categories since 2015. The company's revenue has demonstrated robust growth, with VEVYE reporting a 22% quarter-over-quarter increase, reaching $22.6 million, and achieving a 10.5% share of the national dry eye disease market by the end of the third quarter of 2025. Analysts anticipate Harrow's quarterly revenue run rate to exceed $250 million by the fourth quarter of 2027, representing a significant increase compared to prior periods, supported by strong prescription growth momentum and a solid product pipeline.
Bears say
Harrow Inc. faces significant risks that could adversely affect its stock valuation, particularly if the clinical and regulatory outcomes of its product spinouts are unfavorable. The company’s reliance on the successful adoption of its pharmaceutical assets is critical, and any shortfall in market uptake or delays in regulatory approvals could materially impact its financial position. Additionally, Harrow's limited resources may hinder its ability to effectively market its products, potentially necessitating capital raises that could dilute existing shareholder value.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares